SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-000362
Filing Date
2023-01-19
Accepted
2023-01-19 16:14:02
Documents
17
Period of Report
2023-01-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20230118x8k.htm   iXBRL 8-K 44720
2 EX-1.1 kala-20230118xex1d1.htm EX-1.1 327368
3 EX-5.1 kala-20230118xex5d1.htm EX-5.1 19971
4 GRAPHIC kala-20230118xex5d1002.jpg GRAPHIC 3950
5 GRAPHIC kala-20230118xex5d1003.jpg GRAPHIC 16377
6 GRAPHIC kala-20230118xex5d1001.jpg GRAPHIC 3961
  Complete submission text file 0001558370-23-000362.txt   610642

Data Files

Seq Description Document Type Size
7 EX-101.SCH kala-20230118.xsd EX-101.SCH 3126
8 EX-101.LAB kala-20230118_lab.xml EX-101.LAB 15266
9 EX-101.PRE kala-20230118_pre.xml EX-101.PRE 9658
11 EXTRACTED XBRL INSTANCE DOCUMENT kala-20230118x8k_htm.xml XML 4686
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 23537578
SIC: 2834 Pharmaceutical Preparations